Biomarcadores para el Sindrome de Fatiga Cronica

[elipoarch]

Han publicado un nuevo estudio en PlosOne. Os copio aquí el Extracto, para los que usan el traductor automático:

[t]Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26[/t]
Mary A. Fletcher, Xiao R. Zeng, Kevin Maher, Silvina Levis, Barry Hurwitz, Michael Antoni, Gordon Broderick, Nancy G. Klimas

Abstract

Background
Chronic Fatigue Syndrome (CFS) studies from our laboratory and others described decreased natural killer cell cytotoxicity (NKCC) and elevated proportion of lymphocytes expressing the activation marker, dipeptidyl peptidase IV (DPPIV) also known as CD26. However, neither these assays nor other laboratory tests are widely accepted for the diagnosis or prognosis of CFS. This study sought to determine if NKCC or DPPIV/CD26 have diagnostic accuracy for CFS.

Methods/Results
Subjects included female and male CFS cases and healthy controls. NK cell function was measured with a bioassay, using K562 cells and 51Cr release. Lymphocyte associated DPPIV/CD26 was assayed by qualitative and quantitative flow cytometry. Serum DPPIV/CD26 was measured by ELISA. Analysis by receiver operating characteristic (ROC) curve assessed biomarker potential. Cytotoxic function of NK cells for 176 CFS subjects was significantly lower than in the 230 controls. According to ROC analysis, NKCC was a good predictor of CFS status. There was no significant difference in NK cell counts between cases and controls. Percent CD2+ lymphocytes (T cells and NK cells) positive for DPPIV/C26 was elevated in CFS cases, but there was a decrease in the number of molecules (rMol) of DPPIV/C26 expressed on T cells and NK cells and a decrease in the soluble form of the enzyme in serum. Analyses by ROC curves indicated that all three measurements of DPPIV/CD26 demonstrated potential as biomarkers for CFS. None of the DPPIV/C26 assays were significantly correlated with NKCC.

Conclusions
By ROC analysis, NKCC and three methods of measuring DPPIV/C26 examined in this study had potential as biomarkers for CFS. Of these, NKCC, %CD2+CD26+ lymphocytes and rMol CD26/CD2+ lymphocyte, required flow cytometry, fresh blood and access to a high complexity laboratory. Soluble DPPIV/C26 in serum is done with a standard ELISA assay, or with other soluble factors in a multiplex type of ELISA. Dipeptidyl peptidase IV on lymphocytes or in serum was not predictive of NKCC suggesting that these should be considered as non-redundant biomarkers. Abnormalities in DPPIV/CD26 and in NK cell function have particular relevance to the possible role of infection in the initiation and/or the persistence of CFS.

Aquí os pongo el artículo entero, en pdf.

[scrbd]32067535,zvqzpwkepogl5rlhrpo[/scrbd]

[Matallana]

lo teneis ya en castellano en La Plataforma, gracias a Cathy van Riel

http://www.plataformafibromialgia.org/a ... 202010.pdf" onclick="window.open(this.href);return false;

[EndSFC]

Hablábamos de marcadores para diagnósticar el SFC. Bien, aquí tenemos otro, que ha demostrado su efectividad. No he leído más que el resumen, por lo que no puedo opinar en cuanto a la solidez del ensayo, pero es más que evidente que no tenemos marcadores porque no interesa tenerlos, porque haberlos...

http://www.plataformafibromialgia.org/i ... l-sfc.html" onclick="window.open(this.href);return false;

(Arriba encontraréis el estudio entero traducido)

Este es el resumen que realiza la Plataforma para la Fibromialgia, Síndrome de Fatiga Crónica y SSQM

Biomarcadores en el Síndrome de Fatiga Crónica:
Evaluación de la función de las células Natural Killer y de la dipeptidil peptidasa IV/CD26

Este estudio buscó determinar si la NKCC o la DPPIV/CD26 tienen una exactitud diagnóstica para el SFC y aparentemente consiguió encontrar un biomarcador diagnóstico para el SFC.

Antecedentes: Estudios del Síndrome de Fatiga Crónica (SFC) de nuestro y de otros laboratorios
describen una disminuida citotoxicidad de las células natural (NKCC) y una elevada proporción de
linfocitos que expresan el marcador de activación, la dipeptidil peptidasa IV (DPPIV) – también conocida como CD26. No obstante, ni estos ensayos, ni otros tests de laboratorio se aceptan ampliamente para el diagnóstico o la prognosis del SFC.

[elipoarch]

S, te he unido el mensaje a este hilo, que ya estaba iniciado, por si hay algún comentario, tenerlos todos juntos.

[EndSFC]

Ostras, no había leído tu post!!! Si es que somos muuu rápidos! :-)

Thanks,
S.